media

Results affirm the advantages of Prota’s remission peanut OIT treatments, which lead to significant and sustained benefits including substantially improved Health Related Quality of Life

Prota Therapeutics’ CEO Professor Mimi Tang has been honoured in the prestigious 2024 BioMelbourne Network Women in Leadership Awards

First Company to Validate Significant Quality of Life Improvements Compared with Standard Care

Groundbreaking Clinical Trial Data Demonstrates Clinical Remission of Peanut Allergy in Paediatric Patients

Prota Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick Machado

Financing advances development of Prota’s peanut allergy remission therapy in preparation for a Phase 3 clinical trial.

Melbourne, Australia: Allergy immunotherapy company Prota Therapeutics Pty Ltd (Prota) is pleased to announce results from a follow up study of the probiotic and peanut immunotherapy (PPOIT) treatment which it has licensed from the Murdoch Childrens Research Institute (MCRI), demonstrating long-lasting tolerance effects of treatment more than four years after the original study ended.

The research, led by the Murdoch Children’s Research Institute (MCRI), found the treatments – a combination of a probiotic together with oral immunotherapy (the gradual introduction of the allergenic food) and oral
immunotherapy alone – significantly induced remission and desensitisation.